Its decision to quit the stage, at least for now, had been widely expected after AstraZeneca refused its final offer of 55 pounds a share.NEW DELHI: There is need for a foolproof system that can restrict, curb and even eliminate causes leading to adverse drug reactions (ADRs), a top official said today.

Therefore, it becomes more important for India to see that while its drugs manufacturing and their exports registered a manifold increase with no suspicion in their content and quality, he added.

"America for example, set out to address this issue way back in 1962, consequently little number of cases of ADRs are reported there though India also awake to this fact in 1982, we have achieved little progress to contain ADRs. This is because it has not been able to create an effective mechanism to address the issue," Subburaj said.

No definite and effective statistics and estimates are available as to how many cases of ADRs happen each year while in America such statistics are accurate and the system in place, India therefore, needs to emulate such a country to address the issue of ADRs, he said.

Only in India the healthcare financing is very small when compared to the financing by the other forces rather than the patient himself or herself paying out of pocket. Having 70-75% of the expenses as out-of-pocket, in my opinion, is not a right approach to managing healthcare in a country where the patients tend to sub-optimally purchase healthcare if he/she has to pay out-of-pocket.